-
ASH 2024丨Dr. Sumit Gupta: Standard Chemotherapy Combined with BiTE Prolongs Event-Free Survival in Standard-Risk B-ALL Pediatric Patients
From December 7 to 10, 2024, the 66th American Society of Hematology (ASH) Annual Meeting was grandly held in San Diego, USA. Hematology experts and scholars from around the world gathered to discuss and exchange insights on the latest research advancements in the field.
-
ESMO China Voice | Dr. Guodong He: PDNet Model Enables Precise Selection of Patients for Immunotherapy, Significantly Improving Treatment Outcomes
________________________________________ Oncology Frontier: Immunotherapy has advanced rapidly in recent years, making the selection of patients who will benefit from treatment a key clinical challenge. Your ESMO-selected study explored the use…
-
CheckMate 9DW Breakthrough: Nivolumab and Ipilimumab Show Promise as First-Line Therapy for Unresectable Liver Cancer
Study Design and Key Characteristics The study enrolled 668 patients with unresectable HCC who had not previously received systemic therapy. Eligibility criteria required at least one measurable lesion, a Child-Pugh…
-
Paclitaxel Oral Solution Shines in Phase 3 Trial for Advanced Gastric Cancer Second-Line Treatment
Methods The study was conducted across 53 medical centers in China and included patients with unresectable, recurrent, or metastatic gastric cancer who had experienced disease progression after fluoropyrimidine- or fluoropyrimidine…
-
Pravastatin and Liver Fibrosis: Insights from the PROSPER Trial
A recent post-hoc analysis of the PROSPER trial, published in JHEP Reports (2025), highlights the impact of pravastatin in reducing all-cause mortality in elderly patients at risk of liver fibrosis.The…
-
Exploring the Future of Clinical Research in Hodgkin Lymphoma
In this insightful session, Dr. Wei Xu from Jiangsu Provincial People’s Hospital (The First Affiliated Hospital of Nanjing Medical University) shares her expertise on the foundations and clinical advancements in Hodgkin lymphoma (HL) research. This talk delves into key aspects of HL treatment strategies, research breakthroughs, and what the future holds for clinical applications. Don’t…
-
Five-Year CheckMate 649 Update: Nivolumab Plus Chemo Extends Survival for Chinese Gastric Cancer Patients
Background The CheckMate 649 trial demonstrated a clinically meaningful improvement in survival when nivolumab was added to chemotherapy in patients with advanced gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma…
-
Dr. Mehdi Karoui’s Contribution to Advancing Colorectal Anastomosis Healing
A recent study published in Communications Biology explores a promising approach to improving colorectal anastomosis healing using extracellular vesicles (EVs) derived from adipose stromal cells, embedded in a thermoresponsive gel (Pluronic® F127). This innovative strategy aims to reduce post-surgical complications, enhance tissue regeneration, and improve healing outcomes, particularly in patients undergoing radiotherapy.
Connecting Medical Expertise through Media